COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,397 Articles (22,816 medRxiv, 8,581 bioRxiv)

Most recent first Previous |  Page 851: Articles 8501-8510  | Next

High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant
Huygens, S., Oude Munnink, B., Gharbharan, A., Koopmans, M., Rijnders, B.
10.1101/2022.04.06.22273503 — Posted: 2022-04-06
Delta/ Omicron and Omicron/BA.2 co-infections occurring in Immunocompromised hosts
Leuking, R., Narasimhan, M., Mahimainathan, L., mut, A., Liu, Y., Xing, C., Larsen, C., Clark, A. E., SoRelle, J. A.
10.1101/2022.04.04.22273058 — Posted: 2022-04-06
Pandemic-EBT and grab-and-go school Meals: Costs, reach, and benefits of two approaches to keep children fed during school closures due to COVID-19
Kenney, E. L., Walkinshaw, L. P., Shen, Y., Fleischhacker, S. E., Jones-Smith, J., Bleich, S. N., Krieger, J. W.
10.1101/2022.04.06.22273512 — Posted: 2022-04-06
Serious underlying medical conditions and COVID-19 vaccine hesitancy.
Day, D., Grech, L., Nguyen, M., Bain, N., Kwok, A., Harris, S., Chau, H., Chan, B., Blennerhassett, R., Nott, L., Hamad, N., Tognela, A., Hoffman, D., McCartney, A., Webber, K., Wong, J., Underhill, C., Sillars, B., Winkel, A., Savage, M., Loe, B. S., Freeman, D., Segelov, E., CANVACCS, DIABVACCS, and MSVACCS investigators
10.1101/2022.04.06.22273080 — Posted: 2022-04-06
Analysis of immunization, adverse events, and efficacy of a fourth dose of BNT162b2 vaccine
Romero-Ibarguengoitia, M. E., Gonzalez-Cantu, A., Rivera-Salinas, D., Hernandez-Ruiz, Y. G., Armendariz-Vazquez, A. G., Barco-Flores, I. A., Gonzalez-Facio, R., Sanz-Sanchez, M. A.
10.1101/2022.04.05.22273434 — Posted: 2022-04-06
Monitoring of SARS-CoV-2 variant dynamics in wastewater by digital RT-PCR : from Alpha to Omicron BA.2 VOC
Wurtzer, S., Levert, M., Dhenain, E., Accrombessi, H., Manco, S., Fagour, N., Goulet, M., Boudaud, N., Gaillard, L., Bertrand, I., Challant, J., Masnada, S., Azimi, S., Gillon-Ritz, M., Robin, A., Mouchel, J.-M., SIG OBEPINE, , Moulin, L.
10.1101/2022.04.04.22273320 — Posted: 2022-04-06
Predictors for Reactogenicity and Humoral Immunity to SARS-CoV-2 Following Infection and mRNA Vaccination: A Regularized Mixed-Effects Modelling Approach
Williams, E., Kizhner, A., Stark, V. S., Nawab, A., Muniz, D. D., Echeverri Tribin, F., Carreno, J. M., Bielak, D., Singh, G., Hoffer, M. E., Pallikkuth, S., Pahwa, S.
10.1101/2022.04.05.22273450 — Posted: 2022-04-06
Antibody responses to SARS-CoV-2 vaccination in patients with acute leukaemia and high risk MDS on active anti-cancer therapies
Chan, W. Y., Zhu, C., Sanchez, E., Gupta, R., Fielding, A. K., Khwaja, A., Payne, E. M., O'Nions, J.
10.1101/2022.04.05.22273371 — Posted: 2022-04-06
SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: genomic surveillance in Japan from September 2021 to March 2022
Hirotsu, Y., Maejima, M., Shibusawa, M., Natori, Y., Nagakubo, Y., Hosaka, K., Sueki, H., Mochizuki, H., Tsutsui, T., Kakizaki, Y., Miyashita, Y., Omata, M.
10.1101/2022.04.05.22273483 — Posted: 2022-04-06
Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults
Priddy, F. H., Williams, M., Carson, S., Lavender, B., Mathieson, J., Frampton, C., Moreland, N. J., McGregor, R., Williams, G., Brewerton, M., Gell, K., Ussher, J., Le Gros, G.
10.1101/2022.04.05.22273480 — Posted: 2022-04-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).